Monash-led PADDI trial wins award
The Perioperative Administration of Dexamethasone and Infection (PADDI) trial has been honoured by the 2022 Australian Clinical Trials Alliance (ACTA) Excellence in Trial Statistics Award.
Acknowledging, respecting and supporting the diversity and inclusivity of LGBTQIA+ at the Central Clinical School
17 May is an important date for us all to recognise, International Day Against Homophobia, Biphobia, Interphobia and Transphobia (IDAHOBIT).
Nerve stimulation may be potential therapy for leaky gut diseases
Research by Monash Central Clinical School scientists has suggested that stimulating the vagal nerve transcutaneously improves gut permeability and could potentially counter diseases caused by intestinal barrier dysfunction or ‘leaky gut’
Hot topics in MS research: our take on the 2022 MS Australia Scientific conference
Central Clinical School PhD students in the Multiple Sclerosis and Neuroimmunology Genomics and Prognostics Group present their work in the 2022 Progress in MS Research Scientific Conference.
Intestinal worm study highlights role of microbiota
Monash Professor Nicola Harris has for 15 years investigated the intestinal activities of helminths (parasitic worms), making landmark discoveries about them. Published recently in ‘Mucosal Immunology’, her latest paper showed
Surgery registries crucial to improving patient care, researchers say
Monash University Central Clinical School clinician-researchers are behind a push for the Federal Government to urgently implement strategies to overcome barriers to clinical quality registries for surgery.
Monash clinical trials of new drug shows promise for Alzheimer’s disease and dementia
A Monash University-led study has found a promising new treatment for patients with the second-most common form of dementia in people under 60, resulting in a stabilising of escalating behavioural issues, and a reversal of brain shrinkage due to the
New clot-busting drug may improve treatment for stroke patients
A team of Monash University researchers has demonstrated that an innovative drug that removes blood clots improves the outcomes of acute ischaemic stroke and has a promising safety profile.